15-Methylhexadecyl 3,4,5-trihydroxybenzoate

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 15-Methylhexadecyl 3,4,5-trihydroxybenzoate
• 英文别名: 15-methylhexadecyl 3,4,5-trihydroxybenzoate
• 化学式: C₂₄H₄₀O₅
• 分子量: 408.6
• InChiKey: CQVYZLPOGKJCHQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.2
• 重原子数：
  29
• 可旋转键数：
  17
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  87
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• COMPOSITIONS COMPRISING S-ADENOSYLMETHIONINE AND A GALLIC ACID ESTER
  申请人：Methylation Sciences International SRL

  公开号：EP2753336B1

  公开（公告）日：2015-05-06
• NOVEL ADEMETIONINE FORMULATIONS
  申请人：Methylation Sciences International SRL

  公开号：EP3131557A2

  公开（公告）日：2017-02-22
• Compositions Comprising S-Adenosylmethionine and a Gallic Acid Ester
  申请人：Methylation Sciences International SRL

  公开号：US20140220129A1

  公开（公告）日：2014-08-07

  Provided herein are compositions and formulations comprising S-adenosyl-L-methionine (“SAM-e” or “SAMe”) and one or more gallic acid esters. Also provided herein are methods for improving the delivery of SAMe. Compositions and formulations provided herein increase SAMe plasma concentrations and area under the curve (AUC) values. Also provided herein are methods of treating a disease or disorder in a subject by administering compositions or formulations comprising exogenous SAMe and one or more gallic acid esters.
• Compositions comprising S-Adenosylmethionine and a gallic acid ester
  申请人：Methylation Sciences International SRL

  公开号：US20190022119A1

  公开（公告）日：2019-01-24

  Provided herein are compositions and formulations comprising S-adenosyl-L-methionine (“SAM-e” or “SAMe”) and one or more gallic acid esters. Also provided herein are methods for improving the delivery of SAMe. Compositions and formulations provided herein increase SAMe plasma concentrations and area under the curve (AUC) values. Also provided herein are methods of treating a disease or disorder in a subject by administering compositions or formulations comprising exogenous SAMe and one or more gallic acid esters.
• USE OF S-ADENOSYLMETHIONINE FOR PERSONALIZED TREATMENT OF DEPRESSION
  申请人：Zentar LLC

  公开号：US20220031729A1

  公开（公告）日：2022-02-03

  The present invention relates to personalized treatment of depression using S-adenosylmethionine composition.